Catalyst Pharmaceutical Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for CPRX, updated each market day.
CPRX AI Sentiment
AI predicts Catalyst Pharmaceutical Inc. stock is likely to decrease over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Catalyst Pharmaceutical Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
Sector
Exchange
Market Cap
$3,126,371,430
Cap Tier
Employees
182
Headquarters
CORAL GABLES, FL
Listed Since
Nov. 8, 2006
Website
CPRX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
CPRX Volatility
Catalyst Pharmaceutical Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
